Royalty Pharma (RPRX) Citi's 2024 Global Healthcare Conference summary

Portfolio growth and business momentum

• Over 30 products added since 2020 IPO, with most assets still in growth phases and several new launches expected to drive top-line acceleration in 2025.

• Key growth drivers include Tremfya, Trelegy, Evrysdi, and new launches such as Voranigo, Yorvipath, Niktimvo, Rytelo, and Cobenfy.

• Existing portfolio staples like cystic fibrosis, Xtandi, and Erleada remain significant contributors.

• Synthetic royalties are increasingly used to fund late-stage development and commercial launches, with three recent deals for new launches.

• The company maintains a high bar for new investments, focusing on differentiated, first-in-class products.

Policy, market, and capital environment

• Limited exposure to IRA policy changes, with only a few products affected; overall impact expected to be minimal.

• No anticipated changes in tax position or significant impact from broader policy shifts.

• Capital deployment has increased to $2–2.5 billion annually, with potential for further growth as industry capital needs rise.

• Dividend growth targeted at mid-single digits, with share buybacks in place to return capital to shareholders.

• Priority remains reinvestment in new royalties, supported by a strong industry position and rising returns.

Investment process and strategy

• Investment process has evolved with expanded team and aggressive investment in commercial analytics and data resources.

• Focus remains on high-quality assets, with a flexible approach to category and stage, ranging from orphan to large-market drugs.

• Business performance is largely independent of broader biopharma capital market cycles, driven more by aggregate innovation and capital needs.

• Synthetic royalties and long-term partnerships are key differentiators, with repeat deals and strong industry relationships.

• Most team members are developed internally, emphasizing a unique, focused culture and long-term partnership approach.